Work

LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

Year: 2023
Type: article
Language: English
Subfield: Cancer Research
Open Access status: bronze
OpenAlex ID: W4387809682
FWCI: 12
Cites:
Cited by: 150
Related to: 10